AML Panel

Acute Myeloid Leukemia (AML) Panel Information

The HemeScreen® AML Panel offerings are research use only assays that detect somatic mutations in targets of interest related to Acute Myeloid Leukemia (AML). This panel is specifically designed to detect mutations using High Resolution Melt Analysis in FLT3, KIT, IDH1, IDH2, CEBPA and NPM1 genes. This reagent set is designed to be used by suitably trained personnel testing DNA extracted from whole blood or bone marrow samples.

Technical Overview IFU SDS Shop
Acute Myeloid Leukemia Plate Layout
Acute Myeloid Leukemia (AML) Kit

Development Of The HemeScreen AML Panel

Precipio’s own clinical hematopathology laboratory developed the HemeScreen AML panel to address the issues of turn-around time and accurate, comprehensive molecular testing for gene mutations associated with acute myeloid leukemia (AML). By taking a panel approach to gene mutation detection for suspected acute myeloid leukemias, Precipio’s clinical hematopathology lab is able to rapidly identify these gene mutations in a single assay run on one platform. This provides our lab with a more efficient testing workflow and enables rapid turn around time on this acute condition to empower clinicians with critical data to inform targeted treatment decisions .

HemeScreen Acute Myeloid Leukemia (AML) Assay Configurations

The HemeScreen AML panel comes pre-plated with optimized primers and embedded mutant, NTC, and wild type controls for driver mutation genes of interest in AML. This simplifies lab inventory management by providing a complete molecular assay without tracking multiple SKUs of single gene testing assays that require separate control kits. This also provides a rapid solution for the lab to deliver timely answers.

A 1-sample pre-plated, and vialed free flow configurations are available for the AML panel. Custom configurations are also possible for all or individual genes.

HemeScreen Workflow


DNA Workflow

Sample preparation is based off of standard DNA extraction techniques. Most HRM-enabled RT-PCR instruments can run the HemeScreen AML assay after DNA samples are plated. Data is captured in real time and melt curves can be analyzed to determine the mutation status of FLT3, KIT, IDH1, IDH2, CEBPA and NPM1 genes.